Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Fursultiamine
- DrugBank Accession Number
- DB08966
- Background
Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Fursultiamine (DB08966)
- Weight
- Average: 398.543
Monoisotopic: 398.144632098 - Chemical Formula
- C17H26N4O3S2
- Synonyms
- Fursultiamina
- Fursultiamine
- Fursultiaminum
- Thiamin tetrahydrofurfuryl disulfide
- Thiamine tetrahydrofurfuryl disulfide
- TTFD
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Beriberi •••••••••••• •••••••••• •••••••• Used in combination to treat Beriberi Combination Product in combination with: Riboflavin (DB00140) ••• ••• ••••••• •••••• Treatment of Vitamin b1 deficiency •••••••••••• •••••••••• •••••••• Used in combination to treat Vitamin b1 deficiency Combination Product in combination with: Pantothenic acid (DB01783), Pyridoxine (DB00165), Cyanocobalamin (DB00115), Tocopherol (DB11251) ••• ••• ••••••• •••••• Used in combination to prevent Vitamin b1 deficiency Combination Product in combination with: Tocopherol (DB11251), Pantothenic acid (DB01783), Pyridoxine (DB00165), Cyanocobalamin (DB00115) ••• ••• ••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Fursultiamine hydrochloride T3557LWB27 2105-43-3 OPGOLNDOMSBSCW-CLNHMMGSSA-N - International/Other Brands
- Adventan / Alinamin F / Diteftin / Judolor / Linamin
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ALINAMIN EX PLUS Fursultiamine hydrochloride (36.39 MG) + Cyanocobalamin (500 MCG) + Calcium pantothenate (10 MG) + Pyridoxine hydrochloride (33.33 MG) + Vitamin E (33.33 MG) Tablet, sugar coated Oral บริษัท ทาเคดา (ประเทศไทย) จำกัด 2014-04-02 Not applicable Thailand 
ALINAMIN-F ODORLESS TABLET Fursultiamine (50 mg) + Riboflavin (5 mg) Tablet, sugar coated Oral LUEN WAH MEDICAL COMPANY (SINGAPORE) PRIVATE LIMITED 1991-06-21 Not applicable Singapore 
Aronamin Gold Fursultiamine (50 mg/1) + Ascorbic acid (70 mg/1) + Hydroxocobalamin acetate (5.22 ug/1) + Riboflavin tetrabutyrate (2.5 mg/1) + alpha-Tocopherol acetate (20 mg/1) Tablet, film coated Oral OASIS TRADING 2018-11-20 Not applicable US 
FURAMIN Fursultiamine (2.5 mg/ml) + D-glucose monohydrate (200 mg/ml) Injection Meprofarm 2016-08-31 2026-02-16 Indonesia 
NEVRAMIN TABLET Fursultiamine (50 mg) + Cyanocobalamin (250 mcg) + Pyridoxine hydrochloride (250 mg) Tablet, sugar coated Oral LUEN WAH MEDICAL COMPANY (SINGAPORE) PRIVATE LIMITED 1991-06-21 Not applicable Singapore - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aronamin Gold Fursultiamine (50 mg/1) + Ascorbic acid (70 mg/1) + Hydroxocobalamin acetate (5.22 ug/1) + Riboflavin tetrabutyrate (2.5 mg/1) + alpha-Tocopherol acetate (20 mg/1) Tablet, film coated Oral OASIS TRADING 2018-11-20 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hydropyrimidines. These are compounds containing a hydrogenated pyrimidine ring (i.e. containing less than the maximum number of double bonds.).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Hydropyrimidines
- Alternative Parents
- Imidolactams / Tetrahydrofurans / Tertiary carboxylic acid amides / Heteroaromatic compounds / Organic disulfides / Sulfenyl compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Primary alcohols show 5 more
- Substituents
- Alcohol / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative show 15 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 05J61265PX
- CAS number
- 804-30-8
- InChI Key
- JTLXCMOFVBXEKD-FOWTUZBSSA-N
- InChI
- InChI=1S/C17H26N4O3S2/c1-12(16(5-6-22)26-25-10-15-4-3-7-24-15)21(11-23)9-14-8-19-13(2)20-17(14)18/h8,11,15,22H,3-7,9-10H2,1-2H3,(H2,18,19,20)/b16-12+
- IUPAC Name
- N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(2E)-5-hydroxy-3-{[(oxolan-2-yl)methyl]disulfanyl}pent-2-en-2-yl]formamide
- SMILES
- C\C(N(CC1=C(N)N=C(C)N=C1)C=O)=C(\CCO)SSCC1CCCO1
References
- Synthesis Reference
U.S. Patent 3,016,380.
- General References
- Kobayashi T, Notoya K, Nakamura A, Akimoto K: Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis. Inflamm Res. 2005 Jun;54(6):249-55. [Article]
- External Links
- PubChem Compound
- 3002119
- PubChem Substance
- 310264929
- ChemSpider
- 2273321
- 4604
- ChEBI
- 135636
- ChEMBL
- CHEMBL1740659
- Wikipedia
- Fursultiamine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Completed Supportive Care Eczema; Contact, Allergic 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, sugar coated Oral Tablet, sugar coated Oral 50 mg Tablet, film coated Oral Injection Tablet, sugar coated Oral 250 mcg Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 132 U.S. Patent 3,016,380. - Predicted Properties
Property Value Source Water Solubility 0.123 mg/mL ALOGPS logP 1.38 ALOGPS logP -0.47 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 15.9 Chemaxon pKa (Strongest Basic) 6.26 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 101.57 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 111.54 m3·mol-1 Chemaxon Polarizability 42.81 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014r-6970000000-ddef6a1ff054816b7853 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00l2-1249000000-53a764a438048c65a434 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-01ow-5690000000-9eba4fe22569421f018a Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0fe0-0291000000-d6dbdb3d74fd2e35bde8 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-014r-9412000000-43bb651cc8f5988189ca Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00dj-7904000000-83b49f3489e1073a286a Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 186.88234 predictedDeepCCS 1.0 (2019) [M+H]+ 189.24033 predictedDeepCCS 1.0 (2019) [M+Na]+ 196.12495 predictedDeepCCS 1.0 (2019)
Drug created at June 09, 2014 15:23 / Updated at February 21, 2021 18:52